All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
GYKI 14451
Known as:
GYKI 14,451
, GYKI-14,451
, GYKI-14451
National Institutes of Health
Topic mentions per year
Topic mentions per year
1980-1994
0
1
1980
1994
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1994
1994
Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin.
D D Callas
,
Peder Bacher
,
Odrika Iqbal
,
Debra A. Hoppensteadt
,
Jawad Fareed
Thrombosis research
1994
Newly developed synthetic and recombinant thrombin inhibitors possess strong anticoagulant effects. Despite these effects…
(More)
Is this relevant?
1992
1992
In vitro inhibition of blood coagulation by tripeptide aldehydes--a retrospective screening study focused on the stable D-MePhe-Pro-Arg-H.H2SO4.
D. Bagdy
,
Éva Barabás
,
Sándor Bajusz
,
Eniko A Széll
Thrombosis and haemostasis
1992
A series of peptide aldehydes synthetized in our institute during the last 15 years were screened to detect their inhibitory…
(More)
Is this relevant?
1990
1990
Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H.
Sándor Bajusz
,
Eniko A Széll
,
+7 authors
E Tomori
Journal of medicinal chemistry
1990
D-Phe-Pro-Arg-H sulfate (GYKI-14166) is a highly active and selective inhibitor of thrombin both in vitro and in vivo. Recent…
(More)
Is this relevant?
1982
1982
Design and synthesis of peptide inhibitors of blood coagulations.
Sándor Bajusz
,
Eniko A Széll
,
Éva Barabás
,
D. Bagdy
Folia haematologica
1982
Inhibition of blood coagulation by peptide aldehydes has been studied. Amino acid sequences were assembled from the P1-P2 portion…
(More)
Is this relevant?
Review
1980
Review
1980
New strategies in the development of anti-atherosclerotic drugs.
Cesare R. Sirtori
,
Eiena Tremoli
,
Riccardo Paoletti
Artery
1980
The results of several recently completed trials of cardiovascular prevention, by the use of hypolipidemic or anti-platelet…
(More)
Is this relevant?